Medipol University

medipol.edu.tr

Total trials

273

Active

79

Phase 3

0

Total enrollment

22,007

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 12 of 12 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Postoperative analgesia management6
Erector spinae plane block2
oral isotretinoin1
Sugammadex1
Standard Postoperative Analgesia1
SPS block1
Surgical Intercostal Blockade.1
serotonin reuptake inhibitor1
local infiltration1
PENG1
FİB1
Serratus posterior superior intercostal plane block1

Next readouts

  • 2025-12-31
  • 2026-05-30
  • 2026-06-01
  • 2026-06-01
  • 2026-09-20
  • 2026-10-01
  • 2026-11-20

Top conditions

  • Cerebral Palsy (CP)7
  • Lumbar Disc Herniation7
  • Lung Diseases6
  • Postoperative Pain5
  • Quality of Life5
  • Stroke5
  • Breast Cancer5
  • Rotator Cuff Syndrome4

Frequently asked questions about Medipol University

How many clinical trials does Medipol University have on ClinicalTrials.gov?
Medipol University is listed as the lead sponsor on 273 clinical trials in ClinicalTrials.gov, 79 of which are currently active (recruiting, enrolling, or ongoing).
How many of Medipol University's trials are in Phase 3?
0 of Medipol University's trials are in Phase 3, spread across 12 active drug programs.
What therapeutic areas does Medipol University focus on?
Medipol University's most-studied conditions on ClinicalTrials.gov are Cerebral Palsy (CP), Lumbar Disc Herniation, Lung Diseases, Postoperative Pain, Quality of Life.
When are Medipol University's next clinical trial readouts?
Medipol University has 7 upcoming primary-completion readouts tracked here; the soonest is “Effect of Systemic Retinoic Acid Use on Micro Ribonucleic Acid (mRNA) Expression”, expected around 2025-12-31.